We are live on ! Find out more
NVS icon

Novartis

1,146 hedge funds and large institutions have $18.5B invested in Novartis in 2021 Q4 according to their latest regulatory filings, with 157 funds opening new positions, 327 increasing their positions, 473 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $688M | Put options by funds: $278M

109% more first-time investments, than exits

New positions opened: 157 | Existing positions closed: 75

6% more funds holding

Funds holding: 1,0801,146 (+66)

3% more capital invested

Capital invested by funds: $18B → $18.5B (+$497M)

0.35% less ownership

Funds ownership: 9.03%8.68% (-0.35%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

31% less repeat investments, than reductions

Existing positions increased: 327 | Existing positions reduced: 473

Holders
1,146
Holders Change
+66
Holders Change %
+6.11%
% of All Funds
17.64%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
157
Increased
327
Reduced
473
Closed
75
Calls
$688M
Puts
$278M
Net Calls
+$410M
Net Calls Change
+$69.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$2.47B -$84.4M -1,016,360 -3%
Primecap Management
2
Primecap Management
California
$1.59B -$74.4M -896,060 -5%
Loomis, Sayles & Company
3
Loomis, Sayles & Company
Massachusetts
$1.57B -$86.8M -1,045,879 -6%
Fisher Asset Management
4
Fisher Asset Management
Washington
$908M +$6.61M +79,637 +0.8%
Franklin Resources
5
Franklin Resources
California
$800M +$196M +2,361,944 +35%
Bank of America
6
Bank of America
North Carolina
$681M -$118M -1,424,172 -15%
Boston Partners
7
Boston Partners
Massachusetts
$409M +$24.3M +292,854 +7%
Charles Schwab
8
Charles Schwab
California
$368M +$7.41M +89,226 +2%
UBS Group
9
UBS Group
Switzerland
$366M -$27.5M -331,179 -7%
Wellington Management Group
10
Wellington Management Group
Massachusetts
$358M -$9.84M -118,480 -3%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$339M +$83.3M +1,003,235 +35%
Renaissance Technologies
12
Renaissance Technologies
New York
$326M +$34.9M +420,333 +13%
Janus Henderson Group
13
Janus Henderson Group
United Kingdom
$311M -$35.4M -426,338 -11%
Morgan Stanley
14
Morgan Stanley
New York
$305M +$22.2M +267,670 +8%
Wells Fargo
15
Wells Fargo
California
$277M -$178M -2,149,285 -40%
Northern Trust
16
Northern Trust
Illinois
$272M -$12.1M -146,325 -4%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$251M +$64.2M +772,900 +37%
CCM
18
Cullen Capital Management
New York
$245M -$16.3M -196,010 -7%
PPA
19
Parametric Portfolio Associates
Washington
$221M -$21.3M -256,939 -9%
Principal Financial Group
20
Principal Financial Group
Iowa
$199M +$17.4M +209,629 +10%
Goldman Sachs
21
Goldman Sachs
New York
$191M +$9.04M +108,936 +5%
State Street
22
State Street
Massachusetts
$171M -$5.03M -60,564 -3%
MNG
23
Manning & Napier Group
New York
$169M +$1.51M +18,232 +1%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$159M +$149M +1,793,934 +6,908%
Two Sigma Investments
25
Two Sigma Investments
New York
$157M +$3.06M +36,833 +2%

NVS Hedge Fund Activity: Q4 2021 in Review

1,146 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2021, worth a combined $18.5B — up 2.8% from $18B a quarter earlier.

Buyers outnumbered sellers: 157 funds opened new NVS positions and 75 closed out — a net gain of 82 holders — while 327 added to existing stakes and 473 trimmed.

The largest buyer was Franklin Resources, adding an estimated $196M. The largest seller was Aristotle Capital Management, cutting an estimated $628M.

  • 1,146 institutional investors held Novartis (NVS) as of Q4 2021, up from 1,080 in Q3 2021.
  • Funds reported $18.5B of Novartis stock for Q4 2021, up 2.8% quarter-over-quarter.
  • 157 funds opened new Novartis positions in Q4 2021 and 75 closed out, a net change of +82 holders.
  • The largest Novartis buyer in Q4 2021 was Franklin Resources, an estimated $196M added.
  • The largest Novartis seller in Q4 2021 was Aristotle Capital Management, an estimated $628M sold.

Based on aggregated 13F filings for Q4 2021.